Global Drugs of Abuse (DOA) Testing Market Size, Trends, and Growth Opportunity, By Product (Consumables, Analyzers, Equipment), By Sample Type (Urine, Saliva, Hair, Others), By Application (Pain Management, Criminal Justice, Workplace Screening), By End Users (Hospitals, Laboratories, Workplace, At Home, Others), By Region and forecast till 2027.
Global Drugs of Abuse (DOA) Testing Market The market for testing for drugs of abuse (DOA) was estimated to be worth USD 7.2 billion in 2021 and is anticipated to grow to USD 8.3 billion by 2027 at a CAGR of 1.98% from 2022 to 2027. Drug Abuse testing is a clinical screening method used to find one or more unlawful substances, such as a drug, chemical, or plant product to which the patient is addicted. Utilizing the patient's urine, saliva, blood, hair, or sweat, this clinical screening procedure. Market Drivers As the production, use, and trafficking of new and illegal drugs increase at an accelerated rate and businesses expand, DoA testing will be in great demand... In 2015, there were 255 million users of illicit drugs worldwide, according to the 2017 World Drug Report of the UN Office on Drugs and Crime. This will make DOA testing necessary, driving the market forward.
The government's initiatives to increase company compliance with DOA testing and raise DOA awareness will benefit the market's overall growth. The increased demand for products with more specificity and sensitivity to designer medications will cause the sector to grow. Leading competitors in the DoA testing market are increasing their product range with novel substances for DoA testing to maintain their competency and market dominance. Shimadzu Corporation, for example, introduced its Smart Forensic Database Ver. 2 in February 2018, including features for analyzing forensic toxicological compounds involved in DoA in biological samples utilizing Gas Chromatograph-Mass Spectrometry. Similarly, Thermo Fisher Scientific Inc. upgraded its library for the Thermo Scientific TruNarc handheld narcotics analyzer in November 2017. The upgrade included 45 new chemicals to the handheld narcotics analyzer, including 14 new types of fentanyl, and it can now detect Carfentanil. Market Restraints The inadequacy of these testing products to detect minute levels of particular medications is predicted to stymie industry expansion.
The alteration of legislation to legalize the use of recreational drugs/illicit substances is likely to challenge the drug of abuse (DOA) testing market during the forecast period. Market Segmentation Global Drugs of Abuse (DOA) Testing Market is segmented into Product, Sample Type, Application, and End-Users. By Products such as Consumables, Rapid test kits, Assay kits, Reagents, Others, Blood, Breath, Analyzers, Equipment, Immunoassay analyzers, Chromatography instruments, and Breath analyzers. By Sample Types such as Urine, Saliva, Hair, and Others. Applications such as Pain Management, Criminal Justice, and Workplace Screening. By End-Users such as Hospitals, Laboratories, workplaces, At Home, and Others. Regional Analysis Global Drugs of Abuse (DOA) Testing Market is segmented into five regions North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Due to the region's widespread use of illegal drugs, rising drug trafficking, and expanded workplace drug testing, North America dominates the drugs of abuse (DOA) testing market.
sia-Pacific is predicted to develop at the fastest rate over the projection period, owing to the region's rising usage of illegal substances and increased corporate adherence to workplace drug testing. Due to the region's widespread use of illegal drugs, rising drug trafficking, and expanded workplace drug testing, North America dominates the drugs of abuse (DOA) testing market. Due to rising illegal drug use and improved corporate adherence to workplace drug testing, Asia-Pacific is expected to grow at the quickest rate during the forecast period.
Key Players This report includes a list of numerous Key Players, namely Stryker Corporation (U.S.), Zimmer Biomet (U.S.), Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Abbott (U.S.), GSK Plc. (U.K.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Germany), F. Medtronic (Ireland), and Homology Medicines, Inc (U.S). Market Taxonomy By Product • Consumables • Rapid test kits • Assay kits • Reagents • Blood • Breath • Analyzers • Equipment • Immunoassay analyzers • Chromatography instruments • Breath analyzers • Others By Sample Type • Urine • Saliva • Hair • Others By Application • Pain Management • Criminal Justice • Workplace Screening By End Users • Hospitals • Laboratories • Workplace • At Home • Others By Region • North America • Latin America • Europe • Asia Pacific • Middle East & Africa
Global Drugs of Abuse (DOA) Testing Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Drugs of Abuse (DOA) Testing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Drugs of Abuse (DOA) Testing Market, By Product
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
5.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Product
5.3.1 Consumables
5.3.2 Rapid test kits
5.3.3 Assay kits
5.3.4 Reagents
5.3.5 Others
5.3.6 Blood
5.3.7 Breath
5.3.8 Analyzers
5.3.9 Equipment
5.3.10 Immunoassay analyzers
5.3.11 Chromatography instruments
5.3.12 Breath analyzers
6 Global Drugs of Abuse (DOA) Testing Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Application
6.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
6.3.1 Pain Management
6.3.2 Criminal Justice
6.3.3 Workplace Screening
7 Global Drugs of Abuse (DOA) Testing Market, By Sample Type
7.1 Y-o-Y Growth Comparison, By Sample Type
7.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Sample Type
7.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
7.3.1 Urine
7.3.2 Saliva
7.3.3 Hair
7.3.4 Others
8 Global Drugs of Abuse (DOA) Testing Market, By End Users
8.1 Y-o-Y Growth Comparison, By End Users
8.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By End Users
8.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By End Users
8.3.1 Hospitals
8.3.2 Laboratories
8.3.3 Workplace
8.3.4 At Home
8.3.5 Others
9 Global Drugs of Abuse (DOA) Testing Market, By Region
9.1 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Region
9.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Region
9.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Region
10 North America Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 North America Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
10.3 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
10.4 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
10.5 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
10.6 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11 Europe Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Europe Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
11.3 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
11.4 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
11.5 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
11.6 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.6.4. Rest of Europe
12 Asia Pacific Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Asia Pacific Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
12.3 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
12.4 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
12.5 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
12.6 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4. Rest of Asia Pacific
13 Latin America Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Latin America Drugs of Abuse (DOA) Testing Market Share Analysis, Product Type
13.3 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
13.4 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
13.5 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
13.6 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, Country
13.6.1. Brazil
13.6.2. Rest of Latin America
14 Middle East Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
14.1 Introduction
14.2 Middle East Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
14.3 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
14.4 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
14.5 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
14.6 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
14.6.1. Saudi Arabia
14.6.2. UAE
14.6.3. Egypt
14.6.4. Kuwait
14.6.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Takeda Pharmaceutical Company Limited
16.1.1 Overview
16.1.2 Products
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2. F. Hoffmann-La Roche Ltd
16.2.1 Overview
16.2.2 Products
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3. Abbott
16.3.1 Overview
16.3.2 Products
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Medtronic
16.4.1 Overview
16.4.2 Products
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Johnson & Johnson Services, Inc
16.5.1 Overview
16.5.2 Products
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 GSK Plc
16.6.1 Overview
16.6.2 Products
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Bayer AG
16.7.1 Overview
16.7.2 Products
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Zimmer Biomet
16.8.1 Overview
16.8.2 Products
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Stryker Corporation
16.9.1 Overview
16.9.2 Products
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Homology Medicines, Inc
16.10.1 Overview
16.10.2 Products
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
